Assembly Biosciences, Inc. (ASMB), a biotechnology firm, announced promising interim outcomes from its Phase 1b trial involving the use of ABI-4334 in individuals with chronic hepatitis B virus (HBV) infection on Thursday.
The preliminary results from the initial cohort of this study demonstrated significant antiviral efficacy in patients who received a 150 mg dosage of ABI-4334, a cutting-edge capsid assembly modulator (CAM). Furthermore, the investigational drug was well tolerated, exhibiting a positive safety profile.
Recruitment is progressing for the second and final cohort, which will assess a 400 mg dosage of ABI-4334. Findings from this phase are anticipated in the first half of 2025.
According to the collaboration agreement between Assembly Bio and Gilead Sciences, Inc., Gilead retains the option to engage in further development and commercialization of ABI-4334 following the complete data package delivery by Assembly Bio post Phase 1b study completion.
